Press Release

Non-invasive Prenatal Testing (NIPT) Market is Fueled by Trisomy During the Forecast Period

Growing incidence of chromosomal abnormalities and availability of advanced screening technologies is expected to drive the Global Non-invasive Prenatal Testing (NIPT) Market growth in the forecast period, 2024-2028.


According to TechSci Research report, “Non-invasive Prenatal Testing (NIPT) Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018–2028F” Global Non-invasive Prenatal Testing (NIPT) Market stood at USD4.03 billion in 2022 and is expected to grow at a CAGR of 7.38% through 2028. The increasing prevalence of genetic disorders in fetuses is a significant driver for market growth. Moreover, advancements in technology within the life sciences and healthcare industries are providing a substantial boost to the market. For example, the development of DNA sequencing technologies, breakthroughs in molecular research, and regenerative medicines have opened up immense possibilities for early detection and prevention of serious diseases. Additionally, the growing acceptance rate of prenatal testing, coupled with increased health consciousness and awareness among the general population, is driving market growth. Healthcare providers and expecting parents are increasingly turning to alternative diagnostics for genetic disorders such as spina bifida, cleft palate, and sickle cell anemia, enabling early intervention during fetal development. Furthermore, the trend of childbearing at a higher maternal age (35 years or older) is also positively influencing market growth, despite the associated health complications including high blood pressure, reduced fertility, and increased risk of chromosomal anomalies in the fetus.


The demand for Non-Invasive Prenatal Testing (NIPT) is rising in various countries due to several factors. These include an increasing number of doctors opting for advanced genetic testing for high-risk pregnancies, a desire to postpone pregnancy, and a rise in pregnancy-related complications during the second or third trimester. Traditional invasive prenatal testing methods like chorionic villus sampling and amniocentesis can lead to complications such as miscarriage. Consequently, there has been a decline in the utilization of these procedures and a surge in demand for more efficient, noninvasive, and safe tests. NIPT utilizes cell-free fetal DNA (cffDNA) present in the mother's blood to detect common trisomies such as Turner syndrome, Down syndrome, fetal rhesus D status, sex chromosome disorders, and determine fetal sex. The market for NIPT is highly competitive, with numerous key players operating in the field. To maintain a stronghold in the market, companies are forming strategic partnerships and collaborations. For example, in June 2021, Illumina collaborated with Next Generation Genomic to introduce VeriSeq NIPT Solution v2, a CE-IVD, NGS-based NIPT test in Thailand. This collaboration aims to enhance patient access to next-generation sequencing-based NIPT. The market is driven by constant improvements and advancements in existing products. Notably, in April 2020, Natera expanded the coverage of its product Panorama to cater to all pregnant women regardless of age or conditions. The introduction of innovative products is expected to have a positive impact on the market. Moreover, increased reimbursement coverage for newly introduced products is anticipated to further boost product adoption.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Non-invasive Prenatal Testing (NIPT) Market.”


The age of a woman at the time of delivery is commonly referred to as her maternal age. Advancing maternal age can result in various health complications, including decreased fertility, hypertension, and an elevated risk of miscarriage, stillbirths, and maternal mortality. Additionally, due to errors in chromosomal division, maternal age can contribute to a higher incidence of genetic abnormalities in newborns. Neonates may exhibit conditions such as microcephaly, a shortened neck, upward slanted eyes, weak muscle tone, and complications related to the heart, intestines, and respiration. These findings suggest a global increase in maternal advanced age, which is likely to result in more health challenges. Consequently, the rising maternal age, coupled with the growing prevalence of chromosomal abnormalities, is anticipated to drive the demand for non-invasive prenatal testing (NIPT). The increasing occurrence of chromosomal abnormalities, along with expanded applications of NIPT, are key drivers of organic revenue growth in the market. Moreover, advancements in existing tests, encompassing enhanced functionality, improved chemistry, and bioinformatics analysis, are projected to fuel market expansion. The enhancement of payment policies for routine and low-risk pregnancies serves as a primary catalyst for market growth.


Notably, Natera announced in December 2020 that Aetna, the leading U.S. health insurer, would provide coverage for its non-invasive prenatal testing (NIPT) for all pregnancies. One of the primary factors propelling the market for non-invasive prenatal testing (NIPT) is the increasing average maternal age, which has raised concerns regarding fetal well-being. Down syndrome, characterized by the presence of an additional chromosome 21 resulting from a cell division error, can significantly impact a fetus's cognitive abilities and physical development. NIPT screening tests are considered safe for both the mother and the baby, carrying no risk of miscarriage, and exhibiting a detection rate of over 99 percent for Down syndrome cases. According to the National Down Syndrome Society and the Centers for Disease Control and Prevention, approximately one in every 700 babies in the United States is born with Down syndrome, with 80 percent of Down syndrome cases occurring in older mothers. The heightened risk of Down syndrome among older women is driving the market for non-invasive prenatal testing.


The Global Non-invasive Prenatal Testing (NIPT) Market is segmented into product type, test type, method, application, end user, regional distribution, and company.


Based on the application, the market is categorized into Trisomy, Microdeletions Symptoms, and Others. Trisomy holds the largest share in the global NIPT market, encompassing gender identification, diagnosis of monogenic disorders, Klinefelter syndrome, and the Rhesus (Rh) blood type. Trisomy remains the largest application segment in the NIPT market, projected to grow at the highest CAGR during the forecast period. The significant share and rapid growth of this segment can be attributed to factors such as maternal age and the increasing prevalence of chromosomal disorders.


Based on region, North America segment is expected to grow during the forecast period.  In 2022, North America held the largest market share, followed by Europe. The high demand for genetic testing in North America, substantial research and development expenditures, a higher preterm birth rate, a well-established research framework, and increased complicated birth rates are expected to drive the expansion of the North America non-invasive prenatal testing market. Furthermore, the robust reimbursement system in North America also supports the demand for non-invasive prenatal testing in the region.


Major companies operating in Global Non-invasive Prenatal Testing (NIPT) Market are:

  • YOURGENE HEALTH Plc
  • Illumina, Inc.
  • Natera, Inc.
  • Hoffman La Roche Ltd.
  • Perkin Elmer Inc.
  • Laboratory Corporation of America Holdings
  • Eurofins LifeCodex GmbH
  • Progenity, Inc.
  • Genesis Genetics
  • Quest Diagnostics Incorporated


Download Free Sample Report

Customers can also request for 10% free customization on this report.


“NIPT has the potential to be incorporated into routine antenatal care, as indicated by numerous healthcare specialists. Non-invasive prenatal testing is gaining popularity among pregnant women as a safer alternative to amniocentesis, especially as awareness of prenatal genetic concerns grows. Due to the higher rates of miscarriage and complications, non-invasive prenatal testing is expected to become the standard procedure in the future, replacing previous, riskier screening methods. With a detection accuracy above 99 percent and a shorter screening time compared to other prenatal screening methods, NIPT stands out. Limited companies currently offer non-invasive prenatal testing. The market's growth is driven by the higher risk of chromosomal abnormalities with increasing maternal age, the rising incidence of chromosomal aneuploidies among fetuses, the development of advanced non-invasive prenatal testing products, and improvements in reimbursement. Moreover, the increasing awareness of non-invasive prenatal testing and untapped market potential in emerging nations in Asia provide significant revenue growth opportunities for market participants. The growing preference for non-invasive techniques over invasive methods is also attracting market expansion.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.


“Non-invasive Prenatal Testing (NIPT) Market Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product Type (Consumables, Instruments), By Test Type (Materni 21, Harmony, Panaroma, Verifi, NIFTY, Others), By Method (Ultrasound Detection, Biochemical Screening Testing, Cell-Free DNA Maternal Plasma Tests, Fetal Cells in Maternal Blood Tests, Others), By Application (Trisomy, Microdeletion Syndrome, Others), By End User (Diagnostic Laboratories, Hospitals, Others), By Region and Competition”,
has evaluated the future growth potential of Global Non-invasive Prenatal Testing (NIPT) Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Non-invasive Prenatal Testing (NIPT) Market.


Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com

Relevant News